Bloodwork Every Woman on Anavar Should Run in 2026

You took your first 10 mg of anavar three weeks ago. Strength is up, you're leaner, and TikTok is selling you the dream. What TikTok isn't selling you is a 50 percent HDL crash, an SHBG below 10, a free testosterone reading three times the female upper limit, and a fundamental voice frequency drop that doesn't come back.

This is the bloodwork guide nobody writes for women. Dose response numbers from 5 to 20 mg. Female reference ranges so you can read your own labs. The virilization markers that move weeks before your voice does. Stop thresholds by marker. A reversibility timeline for everything anavar touches.

Why female anavar bloodwork is different

The internet treats anavar like a unisex compound at a smaller dose. It isn't. Three things make female anavar bloodwork interpretation different from male.

Women's HDL starts higher. Average premenopausal female HDL is 55 to 70 mg/dL versus 40 to 50 mg/dL for men. When anavar halves your HDL, the percentage drop is comparable to men, but the absolute landing zone ends up in the same low range. A 65 mg/dL baseline crashing to 25 mg/dL erases the estrogen-driven cardiovascular protection you had two months ago. You don't get to brag that women have better lipids than men anymore.

SHBG crashes, free T explodes. Anavar is one of the most aggressive SHBG suppressors in the AAS catalog. At 10 to 20 mg/day, female users routinely see SHBG drop from a baseline of 30 to 90 nmol/L down to under 10 nmol/L. That's a 70 to 90 percent suppression. The Haeusler JCEM 1996 Turner syndrome study saw "dramatic" SHBG decrease at doses as low as 0.0625 mg/kg/day, roughly 3 to 5 mg/day in an adult woman (Haeusler et al., 1996). Total testosterone might double on cycle. Free testosterone can rise 8 to 15 fold because all of it becomes bioavailable. A woman watching only total T gets dangerously false reassurance.

Anavar is a DHT derivative. Finasteride and dutasteride do nothing here. They block the conversion of testosterone to DHT. Oxandrolone IS already in the DHT family, structurally a 17-alpha-methylated derivative of dihydrotestosterone. It bypasses 5-alpha-reductase and hits androgen receptors in scalp, skin, vocal folds, and clitoral tissue directly. There is no pharmacological bypass.

Dose response at 5 mg vs 10 mg vs 15 mg vs 20 mg

This is the table nobody publishes. Direct female RCT data is rare. The cleanest single trial is Mavros 2015: 29 older women, 10 mg/day oxandrolone for 12 weeks alongside resistance training. Statistically significant HDL drop (P = 0.02), significant ALT rise (P = 0.02), LDL unchanged (Mavros et al., 2015). The 20 mg point comes from Schroeder 2004 in older men: HDL fell about 19 mg/dL absolute (roughly 30 to 45 percent from baseline), LDL rose 22 mg/dL (Schroeder et al., 2004). Grunfeld 2006 in HIV patients confirmed dose-dependent HDL crashes at 20, 40, and 80 mg (Grunfeld et al., 2006).

The 5 mg and 15 mg points are interpolated. Be honest with yourself about that.

The dose response is steeper than linear for the androgenic markers. Doubling from 10 to 20 mg roughly doubles the HDL drop but can triple or quadruple the free testosterone spike. This is why community wisdom says "stay at 10, don't push to 20." The bloodwork actually backs that up.

The HDL crash and why women cop it worse

The bigger problem isn't the percentage. It's the mechanism. Hartgens 2004 measured what oral AAS actually do to lipoproteins in self-administered stacks: total HDL dropped 60 percent, but the cardioprotective HDL2 subfraction dropped 76 percent. ApoB rose 38 percent while LDL-C looked mostly normal (Hartgens et al., 2004).

Haffner pinned down the mechanism back in 1983: oral 17-alpha-alkylated AAS upregulate hepatic triglyceride lipase, which catabolizes HDL2 (the protective subfraction) preferentially into HDL3 and beyond (Haffner et al., 1983). Women rely on HDL2 for the cardiovascular advantage they get from estrogen. Anavar strips it.

The LDL trap. A standard lipid panel on anavar can show "normal" LDL-C while ApoB is up 40 percent. Most Australian and US labs don't run ApoB by default. You have to ask. If you only check LDL-C, you miss the most important atherogenic marker in this population. The LDL vs ApoB comparison covers why ApoB is the superior marker on oral AAS.

The triglyceride paradox. Anavar actually lowers triglycerides by 20 to 40 percent via lipoprotein lipase upregulation. Promoters quote this number as a benefit. It isn't. The ApoB and HDL2 collapse override the triglyceride drop completely. If a forum or coach mentions "improved triglycerides" as anavar's metabolic upside, they're either lying or haven't read the literature.

Liver enzymes on anavar in women

Anavar's reputation as the "mildest" 17-AA is true relative to oxymetholone, dianabol, and superdrol. It is not true relative to "no drug at all." About 28 percent of oxandrolone is excreted unchanged by the kidneys, the only oral AAS with a meaningful renal clearance route. That lowers hepatic exposure but doesn't eliminate it. The 17-alpha-alkyl group still produces canalicular bile transporter inhibition at sufficient dose and duration.

What to expect:

• ALT rises 1.5 to 3x ULN, peaks at weeks 4 to 6
• AST follows ALT, slightly smaller magnitude
• GGT often moves only modestly on anavar specifically (less than on dianabol or superdrol)
• Bilirubin and alkaline phosphatase usually stay normal at recreational doses
• Pattern is hepatocellular, not cholestatic, at typical doses

Sex-specific ULN trap. Women's ALT upper limit per ACG 2017 guidelines is roughly 25 U/L, and the original Prati et al., 2002 work that informed those guidelines proposed an even more conservative 19 U/L for women. Either way, it's not the 40 U/L printed on most lab reports. A woman with ALT of 38 U/L is flagged "normal" by her lab but is actually running 1.5x her sex-specific reference. If your lab uses a single unisex cutoff, mentally drop it to 25 to 30 U/L for ALT and 32 U/L for AST before deciding you're fine.

Kiracofe 2019 in burn patients on therapeutic oxandrolone (mostly 20 mg/day) found 42 percent developed transaminitis with ALT or AST above 100 U/L (Kiracofe et al., 2019). That's higher than historical estimates because nobody was looking systematically before.

TUDCA at 250 to 500 mg/day is mechanistically sufficient for the typical female dose. The TUDCA and NAC liver protection article covers the dosing rationale. The oxandrolone-ALT interaction page has the full mechanism.

Virilization markers, the early warning system

This is the most important section of this article. Voice and clitoral changes are partially or fully irreversible. Hair growth follicle changes persist. Your bloodwork moves weeks before any of these become physically obvious.

The chronology:

1. Week 2-3: SHBG crashes first. This is the silent early warning.
2. Week 3-4: Free testosterone spikes second, driven by the SHBG drop more than by total T elevation.
3. Week 4-6: DHT elevates and tissue-level androgen receptor activation begins.
4. Week 6-12+: Physical changes start to show. Voice scratchiness, clitoral sensitivity changes, jawline acne, temple hair recession.

By the time a friend says "your voice sounds different," vocal fold thickening has already happened. Bloodwork is the only early warning system that exists.

Female reference ranges to read your own labs

The Bensoussan case, why blood numbers matter more than feel

In 2019, Bensoussan and Anderson published a 20-year follow-up on a young female bodybuilder whose fundamental frequency dropped well below the normal adult female range (165 to 255 Hz) after a short course of nandrolone (Bensoussan & Anderson, 2019). Two decades and multiple surgical interventions later, her voice still hasn't returned to its pre-cycle pitch. Nandrolone is a different compound to anavar, but the AR mechanism in vocal fold tissue is identical and the lesson holds: you cannot predict your individual sensitivity to virilization, so you monitor.

Strauss 1985, the foundational paper, found all 10 women he interviewed reported voice deepening, clitoral enlargement, and facial hair growth (Strauss et al., 1985). Gruber and Pope 2000 found 76 percent of female AAS users reported at least one adverse medical effect including voice changes, hirsutism, alopecia, menstrual disturbances, clitoral enlargement, and breast atrophy (Gruber & Pope, 2000).

Voice recordings as a biomarker. Read a standardized paragraph at the same time of day, weekly, into your phone's voice memo app. Track subtle fundamental frequency drift before it becomes audible to others. Most ENTs and speech pathologists will measure F0 from a recording for under $200 if you want a clinical number.

Menstrual disruption and HPG axis shutdown

Anavar is the female mirror of male HPTA suppression. Exogenous androgen triggers negative feedback at the hypothalamus, GnRH pulsatility collapses, the pituitary stops releasing LH and FSH, follicular development halts, no ovulation, no luteal corpus, no progesterone.

The numbers from the literature. Korkia and Stimson 1997 found 8 of 13 female AAS users (62 percent) reported menstrual irregularities (Korkia & Stimson, 1997). Strauss 1985 found 7 of 10 (Strauss et al., 1985). The Christou 2017 meta-analysis quantified the suppression: LH dropped roughly 3.4 IU/L and FSH 1.7 IU/L during AAS use, with recovery in 13 to 24 weeks post-cessation (Christou et al., 2017).

Most women miss their first period within 4 to 8 weeks of starting 10 to 20 mg/day. The first sign on bloodwork is luteal-phase progesterone staying flat. Healthy luteal progesterone exceeds 10 nmol/L (3 ng/mL). On cycle it stays follicular-flat below 3 nmol/L. A flat progesterone confirms anovulation even if some breakthrough bleeding still occurs.

The estradiol counter-intuitive. Anavar does not aromatize. Oxandrolone is structurally a 2-oxa DHT derivative. It lacks the substrate structure aromatase needs. Your estradiol stays flat or drops on cycle. The bloating and puffiness women report on anavar is NOT estrogen. It is androgenic glycogen retention plus subcutaneous water shift driven by free T and DHT. Taking an aromatase inhibitor to fix anavar bloat does nothing except crash your already-low estradiol and accelerate bone density loss. Don't.

Birth control masks the signal

A woman on hormonal contraceptive will have a "regular bleed" every month on anavar because the pill's withdrawal bleed has nothing to do with her natural cycle. The pill bleed continues. The HPG axis is still suppressed underneath. Many women see their regular pill bleed and assume the cycle isn't affecting them. It is. Confirm via LH, FSH, and progesterone bloodwork, not by the calendar.

Pregnancy risk, the dangerous detail

Amenorrhea on cycle is NOT contraception. The first post-cycle ovulation typically precedes the first natural bleed by 10 to 14 days, so unprotected sex during apparent amenorrhea has caused unintended pregnancies with anavar still circulating. Anavar exposure during early pregnancy is documented to virilize female fetuses. Use copper IUD or condoms during and for at least 3 months after cessation. Hormonal contraceptives on top of anavar are unreliable for predicting your fertile window because they mask everything.

Week-by-week bloodwork timeline

A practical timeline if you've decided to cycle. Run these panels, not what your GP would order on a routine.

Baseline (pre-cycle):

• Lipids with HDL2/HDL3 fractions if available, ApoB, ApoA-1, Lp(a)
• ALT, AST, GGT, ALP, total bilirubin
• Total T, free T, SHBG, DHT, LH, FSH, estradiol
• Day 21 progesterone (luteal phase) if cycling normally
• Fasting glucose, HbA1c
• Full blood count
• Document a 30-second voice recording reading the same paragraph

Week 2 to 3 (early signal):

• SHBG, free T, total T
• This is where you catch the early androgen load. If SHBG is already under 15 at week 2, your cycle is hitting harder than expected.

Week 4 to 6 (mid-cycle):

• Full lipid panel including ApoB if you can get it
• ALT, AST, GGT
• SHBG, free T, total T, DHT
• LH, FSH
• Voice recording, compare to baseline

Week 8 to 10 (late cycle if running that long):

• Repeat full mid-cycle panel
• Most women should not run past week 6 to 8

4 weeks post-cycle:

• ALT, AST (should have normalized within 2 to 4 weeks)
• SHBG (should be climbing back, full recovery 4 to 8 weeks)
• Free T (should be near baseline within 2 to 4 weeks)
• HDL (still depressed, that's expected)

12 weeks post-cycle:

• Full panel repeat
• HDL should be approaching baseline, but Hartgens 2004 showed markers were still abnormal at 6 weeks, so don't be surprised if 12 weeks is needed
• LH, FSH, progesterone (luteal phase) to confirm HPG axis recovery
• ApoB

Stop thresholds by marker

If any of these trigger, the cycle stops. Not "wait and see." Stops:

• HDL below 30 mg/dL: cardioprotective margin gone
• ALT above 3x female ULN (>75 U/L): hepatic stress beyond what TUDCA can absorb
• AST above 3x female ULN (>95 U/L): same logic
• Total bilirubin rising: cholestatic shift, the more serious pattern
• SHBG below 10 nmol/L: early warning system is offline, you've lost the buffer
• Free testosterone above 130 pmol/L: sustained androgen load that drives irreversible tissue changes
• DHT above 0.7 nmol/L: exceeds female reference, virilization risk is real
• Total T trending toward male range (>1.7 nmol/L sustained): you're now a low-testosterone man on paper
• Any subjective voice change: morning hoarseness, scratchiness, pitch perception by friends, hard to project. Stop. Do not wait for confirmation on a recording. The fundamental frequency drift has already happened.
• Persistent clitoral sensitivity or visible enlargement: partially irreversible
• Jawline or chest acne new onset: dermal AR saturation, also signals hair follicle activation
• Temple hairline recession: early sign of androgenic alopecia

Reversibility, what comes back and what doesn't

The asymmetry is the most important thing to understand before week 1. Your bloodwork is for catching the reversible problems before the irreversible ones surface.

Irreversible or largely irreversible:

• Voice changes. Vocal fold thickening from androgen exposure produces permanent fundamental frequency drop. The Bensoussan 20-year case study showed multiple surgical interventions could not restore pre-cycle pitch. Gerritsma 1994 showed F0 drop happens within a year of nandrolone even when co-administered with HRT, meaning estrogen does NOT block the change (Gerritsma et al., 1994).

Partially reversible:

• Clitoromegaly. Some shrinkage off-cycle within weeks to months. Enlarged glans tissue and connective hypertrophy commonly persist. The Brazilian clitoroplasty case series describes acquired clitoromegaly requiring surgical correction in long-term users.
• Body and facial hair growth. Once terminal hairs convert from vellus, they don't revert. Growth slows after cessation but laser or electrolysis is required for actual removal. Spironolactone or cyproterone post-cycle can slow new growth.
• Scalp hair thinning and androgenetic alopecia. Brinks 2025 found AAS-induced female pattern hair loss can be slowed or improved with cessation plus minoxidil and oral antiandrogens IF caught early (Brinks et al., 2025). Follicular miniaturization that has progressed is not fully reversible.

Reversible, with timelines:

• HDL: 4 to 12 weeks depending on dose and duration. Hartgens 2004 showed HDL was still below baseline at 6 weeks post-cessation in self-administered stacks. The FDA label estimate of "1 month and you're fine" is optimistic.
• SHBG: 4 to 8 weeks for baseline return. Faster than testosterone or gonadotropin recovery.
• Liver enzymes: 2 to 4 weeks for normalization in absence of pre-existing liver disease.
• Free testosterone and DHT: 2 to 4 weeks of stopping (short half-life ~9-10 hours).
• Menstrual cycle: 2 to 6 months for periods to return. The first post-cycle cycle is often anovulatory. Gonadotropin recovery in 13 to 24 weeks per Christou 2017.
• Mood, libido, aggression: Weeks. Gruber and Pope 2000 found 40 percent of female users experienced depressive symptoms during withdrawal, typically resolving within weeks.

Anavar vs primobolan vs winstrol, the women's trio compared

Quick comparison of the three compounds most often debated for women. All three get labeled "female-safe" by promoters. None of them are without trade-offs.

The short version. Primobolan is the gentlest on lipids and joints, but it's injectable, expensive, and faked constantly. Anavar is the middle ground: oral, mild on the liver, but it does crash HDL hard. Winstrol has the worst lipid profile and worst joint impact of the three despite being cheapest. If you must pick, primobolan is the safest harm-reduction option provided the source is real. Anavar second. Winstrol last, and arguably shouldn't be on the list at all for women.

A full oxandrolone versus primobolan comparison page is on the roadmap. For now this table covers the practical decision.

What about peptides instead

The non-androgenic alternatives are worth a serious look. They won't match anavar's strength gains, but they'll deliver body composition shifts without the virilization risk:

• MK-677: oral, raises GH and IGF-1, modest body composition changes. Watch glucose, this is real. See the MK-677 blood sugar monitoring guide.
• Ipamorelin: injectable, cleanest GH secretagogue, no impact on cortisol or prolactin.
• Tesamorelin: GHRH analog, FDA-approved for visceral fat in HIV-related lipodystrophy, used off-label for body composition.
• BPC-157 and TB-500: recovery peptides, not body composition, but useful for joint health if you train hard.

These don't replace anavar's strength gains. They do offer body composition improvement without AR activation in vocal folds, clitoral tissue, and scalp follicles. For a lot of women the question is "do I want a 10 percent strength gain enough to risk a permanent voice change." The answer is often no when framed that way.

Key takeaways

• Women's anavar bloodwork is not a smaller version of men's. SHBG crashes 70 to 90 percent, free testosterone spikes 3 to 10x even when total T moves modestly, and DHT elevates directly without 5-alpha-reductase involvement.
• Run a baseline panel before week 1. Repeat at weeks 4 to 6. Repeat at 12 weeks post-cycle. ApoB is the most under-used and most important marker; push your lab to include it.
• Use female-specific reference ranges. Your lab's ALT cutoff of 40 U/L is a unisex number that masks real elevation. Mentally cut it to 25 to 30 U/L.
• Stop thresholds: HDL below 30, ALT or AST above 3x female ULN, SHBG below 10, free T above 130 pmol/L, DHT above 0.7 nmol/L, total T trending toward male range, any voice change.
• Voice changes are largely permanent. The Bensoussan 20-year case follow-up showed multiple surgical interventions could not restore a young woman's pre-cycle pitch after a short nandrolone exposure. Different compound, identical AR mechanism in vocal fold tissue.
• Anavar does not aromatize. Bloating is androgenic, not estrogenic. Aromatase inhibitors do nothing useful here and will crash your already-low estradiol.
• Hormonal birth control masks HPG-axis suppression. The pill withdrawal bleed is not a real cycle.
• Reversibility: HDL 4-12 weeks, SHBG 4-8 weeks, liver enzymes 2-4 weeks, periods 2-6 months, free T 2-4 weeks. Voice, clitoral hypertrophy, hair growth: partial to none.
• If you must cycle, primobolan injectable is the lowest-virilization-risk option. Anavar is second. Winstrol is the worst for lipids and joints.

---

References

1. Mavros, Y., O'Neill, E., Connerty, M., Bean, J. F., Broe, K., Kiel, D. P., Maclean, D., Taylor, A., Fielding, R. A., and Singh, M. A. F. (2015). Oxandrolone augmentation of resistance training in older women: A randomized trial. Medicine and Science in Sports and Exercise, 47(11), 2257-2267. PubMed
2. Schroeder, E. T., Zheng, L., Ong, M. D., et al. (2004). Effects of androgen therapy on adipose tissue and metabolism in older men. Journal of Clinical Endocrinology and Metabolism, 89(10), 4863-4872. PubMed
3. Grunfeld, C., Kotler, D. P., Dobs, A., Glesby, M., and Bhasin, S. (2006). Oxandrolone in the treatment of HIV-associated weight loss in men: A randomized, double-blind, placebo-controlled study. Journal of Acquired Immune Deficiency Syndromes, 41(3), 304-314. PubMed
4. Hartgens, F., Rietjens, G., Keizer, H. A., Kuipers, H., and Wolffenbuttel, B. H. R. (2004). Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). British Journal of Sports Medicine, 38(3), 253-259. PubMed
5. Glazer, G. (1991). Atherogenic effects of anabolic steroids on serum lipid levels: A literature review. Archives of Internal Medicine, 151(10), 1925-1933. PubMed
6. Haffner, S. M., Kushwaha, R. S., Foster, D. M., Applebaum-Bowden, D., and Hazzard, W. R. (1983). Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism, 32(4), 413-420. PubMed
7. Kiracofe, B., Coffey, R., Jones, L. M., et al. (2019). Incidence of oxandrolone induced hepatic transaminitis in patients with burn injury. Burns, 45(4), 891-897. PubMed
8. Bond, P., Llewellyn, W., and Van Mol, P. (2016). Anabolic androgenic steroid-induced hepatotoxicity. Medical Hypotheses, 93, 150-153. PubMed
9. Prati, D., Taioli, E., Zanella, A., et al. (2002). Updated definitions of healthy ranges for serum alanine aminotransferase levels. Annals of Internal Medicine, 137(1), 1-10. PubMed
10. Bensoussan, Y., and Anderson, J. (2019). Case report: The long-term effects of anabolic steroids on the female voice over a 20-year period. Clinical Case Reports, 7(5), 1067-1070. PubMed
11. Gerritsma, E. J., Brocaar, M. P., Hakkesteegt, M. M., and Birkenhäger, J. C. (1994). Virilization of the voice in post-menopausal women due to the anabolic steroid nandrolone decanoate. Clinical Otolaryngology and Allied Sciences, 19(1), 79-84. PubMed
12. Strauss, R. H., Liggett, M. T., and Lanese, R. R. (1985). Anabolic steroid use and perceived effects in ten weight-trained women athletes. JAMA, 253(19), 2871-2873. PubMed
13. Gruber, A. J., and Pope, H. G. Jr. (2000). Psychiatric and medical effects of anabolic-androgenic steroid use in women. Psychotherapy and Psychosomatics, 69(1), 19-26. PubMed
14. Korkia, P., and Stimson, G. V. (1997). Indications of prevalence, practice and effects of anabolic steroid use in Great Britain. International Journal of Sports Medicine, 18(7), 557-562. PubMed
15. Haeusler, G., Schmitt, K., Blümel, P., Plöchl, E., Waldhör, T., and Frisch, H. (1996). Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner's syndrome. Journal of Clinical Endocrinology and Metabolism, 81(2), 536-541. PubMed
16. Christou, M. A., Christou, P. A., Markozannes, G., et al. (2017). Effects of anabolic androgenic steroids on the reproductive system of athletes and recreational users: A systematic review and meta-analysis. Sports Medicine, 47(9), 1869-1883. PubMed
17. Nieschlag, E., and Vorona, E. (2015). Mechanisms in endocrinology: Medical consequences of doping with anabolic androgenic steroids. European Journal of Endocrinology, 173(2), R47-R58. PubMed
18. Havnes, I. A., Jørstad, M. L., Innerdal, I., and Bjørnebekk, A. (2021). Anabolic-androgenic steroid use among women: A qualitative study. International Journal of Drug Policy, 95, 102876. PubMed
19. Santos, B. M., de Souza, J. P. A., Goulart, L. R. D. P., et al. (2024). Impacts of Anabolic-androgenic steroid supplementation on female health and offspring. Saudi Pharmaceutical Journal, 32(12), 102205. PubMed
20. Piatkowski, T., Whiteside, B., Robertson, J., Henning, A., Lau, S., and Dunn, M. (2024). What is the prevalence of anabolic-androgenic steroid use among women? A systematic review. Addiction, 119(12), 2088-2100. PubMed
21. Brinks, A. L., Needle, C. D., Spindler, A. J., et al. (2025). Alopecia in female athletes using androgenic and anabolic steroids: Pathophysiology and management. International Journal of Dermatology. PubMed
22. Baker, J. (1999). A report on alterations to the speaking and singing voices of four women following hormonal therapy with virilizing agents. Journal of Voice, 13(4), 496-507. PubMed